期刊
BIOMOLECULES
卷 11, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/biom11030438
关键词
alendronate; M-CSF; osteoclastogenesis; RANKL
资金
- Czech Science Foundation [18-09306S]
The study evaluated the effects of different concentrations of ALN on osteoclastogenesis, indicating that low concentrations promoted osteoclast formation while high doses demonstrated cytotoxic effects.
Bisphosphonates (BPs) are compounds resembling the pyrophosphate structure. BPs bind the mineral component of bones. During the bone resorption by osteoclasts, nitrogen-containing BPs are released and internalized, causing an inhibition of the mevalonate pathway. As a consequence, osteoclasts are unable to execute their function. Alendronate (ALN) is a bisphosphonate used to treat osteoporosis. Its administration could be associated with adverse effects. The purpose of this study is to evaluate four different ALN concentrations, ranging from 10(-6) to 10(-10) M, in the presence of different combinations of M-CSF and RANKL, to find out the effect of low ALN concentrations on osteoclastogenesis using rat and human peripheral blood mononuclear cells. The cytotoxic effect of ALN was evaluated based on metabolic activity and DNA concentration measurement. The alteration in osteoclastogenesis was assessed by the activity of carbonic anhydrase II (CA II), tartrate-resistant acid phosphatase staining, and actin ring formation. The ALN concentration of 10(-6) M was cytotoxic. Low ALN concentrations of 10(-8) and 10(-10) M promoted proliferation, osteoclast-like cell formation, and CA II activity. The results indicated the induction of osteoclastogenesis with low ALN concentrations. However, when high doses of ALN were administered, their cytotoxic effect was demonstrated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据